Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Seminar
November 27, 2006
- Torrent of Questions on FTC Regarding "Joint Purchases" at Ryukaikon
November 27, 2006
- MPC Determined to Expand Business Infrastructure in US, China
November 27, 2006
- REGULATORY NEWS IN BRIEF
November 27, 2006
- Ono to Return to Growth Track in FY2007: Mr Korekane
November 27, 2006
- MEDICAL DEVICE NEWS IN BRIEF
November 27, 2006
- Mochida: Epadel, Atelec Drive Business
November 27, 2006
- SURVEY 3 articles
November 27, 2006
- Toyama Chemical: Net Profits Down Despite Growth in Sales
November 27, 2006
- NEW PRODUCTS
November 27, 2006
- Yakult Aims to Become Oncology-Centered Specialty Pharma
November 27, 2006
- Overseas Business Drives Sales, Profits of 4 Domestic Megas in 1st Half of FY2006
November 27, 2006
- BUSINESS NEWS IN BRIEF
November 27, 2006
- Sawai May Consider Comprehensive Alliance with New Drug Makers
November 27, 2006
- Towa Pharmaceutical: Sales Rise 12.2% to \13,324 Mil.
November 27, 2006
- Nippon Chemiphar: Sales of GE Drugs Up 18% in 1st Half
November 27, 2006
- JMA Members' View of Generics: Follow-up Report
November 27, 2006
- Covance CRU Honolulu Conducts Bridging Studies in Japanese, MD Studies: Dr Ruckle
November 27, 2006
- 46th Annual Scientific Meeting of JSNM
November 27, 2006
- R&D NEWS IN BRIEF
November 27, 2006
ページ
Japan will overhaul its R&D tax credit regime in its FY2026 reform, introducing a new strategic category alongside existing frameworks.…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…